Ocular findings in patients treated with PUVA.
This 5-year prospective study of ophthalmologic findings in 1299 patients treated with oral 8-methoxypsoralen photochemotherapy (PUVA) for psoriasis failed to demonstrate a significant dose-dependent increase in the risk of developing symptomatic cataracts. These patients were instructed to wear UVA-blocking eyeglasses when exposed to sunlight and during treatment for a 12-h period beginning from the time of 8-methoxypsoralen ingestion. However, we did observe a small increase in the risk for development of nuclear sclerosis and posterior subcapsular opacities among patients who received at least 100 PUVA treatments, compared to patients with fewer than 100 treatments (relative risk = 2.3 and 3.0, respectively; p less than .05 both comparisons). We compared our results to those of a large, population-based study and found, after adjusting for differences in methods, that the prevalence of cataracts in our study patients, aged 52-75 years, was not significantly different. Since the latency period for development of symptomatic ocular abnormalities may be longer than 5 years, continued surveillance of our cohort and continued use of appropriate ocular protection by all patients treated with PUVA is indicated.
D000368:Aged; D000375:Aging; D002386:Cataract / Q000209:etiology; D002830:Choroid Neoplasms / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007905:Lens Diseases / Q000503:physiopathology; D007908:Lens, Crystalline / Q000187:drug effects*; D008545:Melanoma / Q000139:chemically induced; D008875:Middle Aged; D011701:PUVA Therapy / Q000009:adverse effects; D010778:Photochemotherapy / Q000009:adverse effects; D011446:Prospective Studies; D014792:Visual Acuity